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ABSTRACT 
The relationship between leptin, insulin resistance and other hormonal parameters in polycys-
tic ovarian syndrome (PCOS) is controversial. We investigated the effect of metformin on 
leptin levels in women with PCOS. Thirty women with PCOS received metformin 500 mg 
thrice a day. After two months of metformin treatment the mean leptin levels reduced signifi-
cantly (p < 0.001). Ovulation was achieved in 28 patients, who also had a significant reduc-
tion in leptin levels (p < 0.001). Leptin showed significant positive correlation with weight 
(p < 0.05) and testosterone (p < 0.01), but no significant correlation with insulin. It is con-
cluded that metformin reduces leptin resistance in PCOS women which induces ovulation. 
Leptin shows a significant correlation with testosterone and not with insulin. 
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INTRODUCTION 
Leptin, a 167 amino acid peptide of tu-
mor necrosis factor family of cytokines 
(Ahima and Flier, 2000), secreted from adi-
pocytes in pulsatile fashion (Caprio et al., 
2001), regulates energy homeostasis by re-
gulating food intake and energy balance 
(Campfield et al., 1995). Leptin levels fall 
during weight loss and increase the brain 
activity in areas involved in the control of 
food intake while restoration of leptin lev-
els maintained weight loss and reversed the 
changes in the brain activity (Ahima, 2008).  
Leptin has also got a permissive role in 
pathogenesis of reproduction (Kennedy and 
Mitra, 1963). Abundant leptin receptors 
have been detected in ovarian granulosa 
and theca cells (Karlsson et al., 1997). Lep-
tin treatment of these cells in vitro caused 
significant reduction in steroid output 
(Spicer and Francisco, 1997). According to 
Frisch’s hypothesis, a critical percent of 
body fat is required for maintenance of re-
productive function (Frisch, 1984). So, in 
conditions of starvation, when body energy 
is insufficient, reproductive function takes a 
back seat to support essential metabolism 
for survival (Wade et al., 1996). Reduced 
weight is associated with low leptin levels. 
However, why overweight patients with 
hyperleptinemia also have reproductive 
dysfunction is still intriguing.  
A study reports that leptin and insulin 
receptor deficient mice showed elevated 
testosterone, infertility and insulin resis-
tance, which are reminiscent of Poly Cystic 
Ovarian Syndrome (PCOS) in humans 
(Caro et al., 1996a). So, in an attempt to 
indirectly learn about leptin and ovarian 
function, PCOS has been targeted for stud-
ies. In PCOS, endocrinological dysregula-
tion is manifested as hyperandrogenism and 
anovulation. However, in the last 15 years, 
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insulin resistance has been identified as a 
significant contributor to the metabolic and 
reproductive abnormalities in PCOS (Dia-
manti-Kandarakis, 2008).  
Leptin resistance was introduced in an 
apparent analogy with that of insulin resis-
tance to explain why hyperleptinemia asso-
ciated with obesity fails to correct the de-
fect in energy balance and feeding behav-
ior. According to Farooqi et al. (2002), 
leptin binds to its receptor in hypothalamus 
and activates JAK-STAT 3 pathway leading 
to suppression of Neuropeptide Y and 
Agouti-related protein (peptides which in-
crease food intake) and secretion of Pro-
opiomelanocortin and Corticotropin releas-
ing hormone (peptides which reduce food 
intake). In obesity, the transport of leptin 
across the blood brain barrier is diminished 
and levels of SOCS 3, an inhibitor of leptin 
signaling is increased in hypothalamus, 
which leads to leptin resistance (Farooqi et 
al., 2002; Oral et al., 2002).  
Metformin is an antidiabetic drug with 
anorexigenic properties. Metformin appears 
to affect ovarian function in a dual mode, 
through the alleviation of insulin resistance 
on ovary and through direct effect on ovary. 
It reduces CYP17 activity in theca cells and 
reduces steroidogenesis in women with 
PCOS (Nestlerand Jakubowicz, 1996). Met-
formin also suppresses androstenedione A4 
production which increases in an insulin 
independent action (Attia et al., 2001). It 
also has modest effect on adipose tissue. A 
study shows that metformin stimulates ca-
tabolism, increases glucose transport and 
utilization, mitochondrial and peroxismal 
FA beta oxidation, basal lipolysis and aero-
bic and anaerobic respiration (Lenhard et 
al., 1997). 
In the present study, leptin levels are 
evaluated in PCOS women before and after 
treatment with metformin and they are fur-
ther correlated with other hormonal pa-
rameters. 
 
MATERIAL AND METHODS 
This study was performed on 30 PCOS 
women in reproductive age group (15-35 
years). Institutional ethics committee ap-
proved the study. Written consent of all the 
patients was taken before enrollment. The 
diagnosis of PCOS was based on history of 
oligomenorrhea, infertility, elevated 
LH/FSH ratio, elevated androgens and re-
duced progesterone. All patients were 
anovular at the time of enrollment, as evi-
denced by the serum progesterone assays. 
All the patients had polycystic ovaries 
(PCO), as seen in ultrasonography (USG). 
No patient had any other endocrinopathy. 
They had not been on any hormonal medi-
cation for at least 3 months before the 
study. No patient had cardiac, renal or he-
patic disease. At the time of enrollment, all 
routine investigations were done. Weight, 
height and BMI were noted. After overnight 
fasting, fasting blood glucose levels were 
noted and samples were drawn for serum 
insulin, serum leptin, serum progesterone 
and serum testosterone. The patients re-
ceived 500 mg metformin tablets thrice a 
day (Glenmark Pharmaceuticals Ltd.) for 
2 months. The treatment was started in the 
menstrual phase or the follicular phase (as 
seen in USG). The patients were asked to 
maintain a menstrual calendar and to note 
any side effects throughout the study pe-
riod. Patients were followed up every 
month for follicle monitoring by USG from 
10th day of the last menstrual period at 
2 day interval for 5-6 times. Any pregnancy 
during the treatment period was recorded. 
At the end of 2 months, all the routine in-
vestigations were done and USG was re-
corded. Venous blood sample was taken for 
estimation of progesterone, testosterone, 
insulin and leptin. The hormonal assays 
were carried out by ELISA technique. 
ELISA kits for leptin and insulin were sup-
plied by DRG laboratories Ltd. ELISA kits 
for progesterone and testosterone were sup-
plied by Dia Metra Laboratory Limited.  
Paired t test was employed for statistical 
analysis of the parameters within the group 
at the baseline and after 2 months of treat-
ment. Chi square test was employed to find 
statistical significance of ovulation. Pear-
son’s correlation test was employed for 
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evaluating correlation between all the pa-
rameters. Statistical analysis was done by 
SPSS version 10.0 statistical software. The 
value of p < 0.05 was taken as significant. 
 
RESULTS 
The PCOS women displayed significant 
benefit after 2 months treatment with met-
formin (Table 1). The weight and BMI re-
duced significantly after metformin treat-
ment (p < 0.001). The fasting glucose levels 
showed a significant reduction (p < 0.001). 
The hormonal assays showed significant 
reduction in the levels of insulin, leptin and 
testosterone (p < 0.001), while a significant 
increase in progesterone levels (p < 0.01). 
Ovulation was achieved in 93.33 % women. 
The mean leptin levels after 2 months of 
treatment in metformin group reduced sig-
nificantly (9.6 ± 1.1 to 5.8 ± 0.71 ng/ml) 
(p < 0.001). However, the leptin levels were 
found to be in the normal range (6.6-11.0 
ng/ml according to the American Medical 
Association) (Iverson et al., 2007). 
On analyzing leptin and ovulation rate, 
it was found that in 28 patients, who had 
ovulation, the mean leptin levels decreased 
significantly from 9.91 ± 1.7 ng/ml to 
5.96 ± 0.75 ng/ml (p < 0.001). In 2 patients, 
who had remained anovular even after the 
treatment, the mean leptin levels reduced 
from 6.5 ± 0 ng/ml to 4.75 ± 2.12 ng/ml, 
which was not significant. Ovulation was 
achieved only with significant reduction in 
leptin levels (Table 2). 
Table 1: Comparison of clinical, biochemical 
and endocrinological data of all the study pa-
tients 
** p < 0.01, *** p < 0.001, compared to the val-
ues in the same group at baseline 
 
On applying Pearson’s correlation test 
to all the parameters, it was seen that leptin 
showed significant positive correlation with 
weight (p < 0.05) and testosterone 
(p < 0.01), but no significant correlation 
with insulin (Table 3). 
 
Table 3: Correlation of serum leptin levels with 
other parameters  
Parameters 
Metformin (n=30) 
Coefficient of  
correlation - r 
Weight (kg) 0.4221** 
BMI (kg/m2) 0.3222* 
Testosterone 
(pg/m) 0.4909** 
Insulin (µIU/ml) 0.0869 
* p < 0.05, ** p < 0.01 
 
Table 2: Comparison of serum leptin levels and ovulation  
Parameters (Mean ± SE) (n=28) 
(Mean ± SE) 
(n=2) 
 Baseline After 2 months Baseline After 2 months 
Leptin (ng/ml) 9.91 ± 1.7 5.96 ± 0.75*** 6.5 ± 0 4.75 ± 2.12 
Ovulation Absent Present*** Absent Absent 
*** p < 0.001 compared to the values in the same group at baseline 
(Mean ± SE) 
n=30 Parameters 
Baseline After 2 months
Weight (kg) 63.7 ± 3.0 61.0 ± 2.7*** 
Body Mass 
Index (BMI) 
(kg/m2) 
24.42 ± 1.0 23.3 ± 0.95*** 
Fasting Blood 
glucose 
(mg/dl) 
102.3 ± 2.7 92.2 ± 2.02*** 
Insulin 
(µIU/ml) 23.0 ± 1.8 15.9 ± 1.3*** 
Leptin (ng/ml) 9.6 ± 1.1 5.8 ± 0.71*** 
Progesterone 
(ng/ml) 1.05 ± 0.19 5.3 ± 0.62*** 
Testosterone 
(pg/ml) 1.2 ± 0.18 0.64 ± 0.16** 
Ovulation  
Present 0 28 (93.33%)*** 
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DISCUSSION 
Adiposity and metabolism have long 
been shown to regulate reproductive func-
tion, and leptin is believed to be a key hor-
mone subserving this physiologic relation-
ship (Ahima et al., 1996). The present study 
reported that treatment with metformin 
brought a significant reduction in weight, 
BMI, fasting blood glucose, testosterone, 
insulin and leptin levels and an increase in 
progesterone levels, which resulted in an 
increase in ovulation rate (Table ). Al-
though leptin concentration is closely re-
lated to body fat mass, yet the reduction in 
leptin levels cannot be fully explained by 
the reduction in weight and BMI, because 
metformin is found to reduce leptin concen-
tration even in normal weight healthy pa-
tients (Glueck et al., 2001; Fruehwald-
Schultes et al., 2002). Several researches 
have been done to analyse the molecular 
mechanism behind the effect of metformin 
on leptin levels. An in-vitro study reports 
that metformin inhibits leptin secretion by 
inhibiting MAPK signaling pathway in adi-
pocytes (Klein et al., 2004). Considering 
the hypothesis that PCOS is characterized 
by leptin resistance, a study showed that 
metformin restores leptin sensitivity in 
obese rats with leptin resistance and met-
formin treatment increased CSF leptin con-
centrations in both standard chow and high-
fat–fed obese rats compared with the un-
treated rats (Kim et al., 2006). It is sug-
gested that the increase in CSF leptin level 
may be the cause of reduced resistance be-
cause the defect in leptin transport through 
the blood-brain barrier is a possible mecha-
nism of leptin resistance (Caro et al., 
1996b; Couce et al., 2001; Nam et al., 
2001). Kim et al. (2006) also reported that 
metformin increased hypothalamic POMC 
(an anorexigenic peptide) expression by 
leptin treatment in high-fat–fed obese rats, 
whereas this was not observed in untreated 
high-fat–fed obese rats. As the effect of 
leptin is associated with the activation of 
POMC (Kim et al., 2005), failure to activate 
POMC expression by leptin is an evidence 
of leptin resistance. 
In our study, we have found a strong as-
sociation between leptin and ovulation rate 
(Table 2). This finding is supported by a 
study which reports that leptin induces fol-
licular development in ob/ob mice and for-
mation of corpora lutea and ovulation in 
hypogonadal mice (Barkan et al., 2005). 
Another study showed that rats subjected to 
severe food restriction had reduction in 
ovulation and serum progesterone. Leptin 
administration to these rats enhanced the 
ovulatory process and prevented the nega-
tive effects produced by malnutrition (Ro-
man et al., 2005). However, a study reports 
negative effect of leptin on ovulation in rat 
ovary model. In this study, leptin admini-
stration resulted in fewer ovulations (Dug-
gal et al., 2000). 
In the present study, leptin levels were 
within normal limits in PCOS patients at 
baseline. One reason can be that the patients 
in this study were not in the obese category. 
Rouru et al. (1997) also reported similar 
serum leptin levels in PCOS and control 
subjects. They reported that serum leptin 
levels are related to BMI and weight, but 
are not significantly different in PCOS and 
control subjects. It has been reported in 
both in vitro (Kennedy et al., 1997) and in 
vivo (Kolacynski et al., 1996) studies that 
hyperinsulinemia stimulates leptin produc-
tion from adipocytes. However, the normal 
leptin levels found in this and other studies  
lead to a possibility that insulin resistance at 
the levels of adipocytes counteracts the 
stimulatory impact of hyperinsulinemia and 
it may account for the maintenance of nor-
mal levels of serum leptin in PCOS (Laugh-
lin et al., 1997; Mantzoros et al., 1997). 
Serum leptin levels showed significant 
positive correlation with weight, BMI and 
testosterone, but did not show any correla-
tion with insulin levels (Table 3). Similarly, 
Erturk et al could not find any correlation 
between leptin and insulin levels (Erturk et 
al., 2004). The role of androgens in the 
regulation of leptin secretion is also contro-
versial (Iuorno et al., 2007). Correlation 
between leptin and testosterone can be sub-
stantiated by the direct effect of leptin on 
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steroidogenesis. Karlsson et al. (1997) have 
reported that immunoreactive leptin acts on 
leptin receptors in ovaries (granulosa and 
theca cells) and suppresses LH induced es-
tradiol production. It may promote a steroid 
microenvironment in the follicle similar to 
that present in PCOS (Erickson et al., 
1979). It can be said that a significant de-
crease in leptin levels is associated with a 
decrease in androgen concentration, hence 
an increase in ovulation rate. Using the rat 
as a model, Castrogiovanni and colleagues 
(2003) demonstrated that the administration 
of testosterone results in an increase in both 
leptin turnover and clearance. In contrast, 
Brzechffa et al. (1996) reported that women 
who are relatively more insulin resistant 
and who exhibit high serum androgen levels 
have higher serum leptin concentrations 
than do normal women. However, Krot-
kiewski and colleagues (2003) demon-
strated that neither the acute reduction of 
serum androgen with a gonadotropin-
releasing hormone agonist nor the admini-
stration of antiandrogens in women with 
PCOS alters serum leptin concentrations. 
Moreover, Remsberg and colleagues (2002) 
have shown that lean women with PCOS 
who manifest higher androgen but lower 
insulin levels have lower serum leptin con-
centrations when compared with BMI-
matched normal women. These observa-
tions suggest that insulin rather than andro-
gen is the primary factor regulating leptin 
secretion, a conclusion that is consistent 
with our current findings. 
 
CONCLUSION  
Metformin reduces leptin resistance and 
increases ovulation in PCOS women. 
Leptin correlates  with testosterone and 
BMI, but does not correlate with insulin 
levels. Significant reduction in leptin levels 
also induces ovulation. 
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